Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.58 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.40 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.40 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL342779 | 0.93 | TSHR (0.72) | TSHRCYP3A4LPAR3LPAR1LPAR2 | |
| SCHEMBL27042141 | 0.90 | TSHR (0.68) | TSHRCYP3A4LPAR3LPAR1LPAR2 | |
| SCHEMBL27042289 | 0.90 | TSHR (0.68) | TSHRCYP3A4LPAR3LPAR1LPAR2 | |
| SCHEMBL27042152 | 0.90 | TSHR (0.68) | TSHRCYP3A4LPAR3LPAR1LPAR2 | |
| SCHEMBL6273276 | 0.90 | CYP3A4 (0.62) | TSHRCYP3A4LPAR3LPAR1LPAR2 | |
| SCHEMBL27042377 | 0.87 | TSHR (0.72) | TSHRCYP3A4LPAR3LPAR1LPAR2 | |
| SCHEMBL6273020 | 0.87 | CYP3A4 (0.59) | TSHRCYP3A4LPAR3LPAR1LPAR2 | |
| SCHEMBL8533131 | 0.87 | CYP3A4 (0.59) | TSHRCYP3A4LPAR3LPAR1LPAR2 | |
| SCHEMBL3816946 | 0.86 | CYP3A4 (0.73) | TSHRCYP3A4LPAR3LPAR1LPAR2 | |
| SCHEMBL1295773 | 0.86 | CYP3A4 (0.73) | TSHRCYP3A4LPAR3LPAR1LPAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140315834-A1 | COMPOUNDS AND COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF INFLAMMATION-RELATED DISORDERS, PAIN AND FEVER, SKIN DISORDERS, CANCER AND PRECANCEROUS CONDITIONS THEREOF | MEDICON PHARMACEUTICALS, INC. (US) | 2014-10-23 | — | — | US | disclosed |
| US-20140088045-A1 | PRODUCT COMPRISING A NICOTINE-CONTAINING MATERIAL AND AN ANTI-CANCER AGENT | RIGAS BASIL (US) | 2014-03-27 | — | — | US | disclosed |
| US-20130225529-A1 | PHOSPHO-ESTER DERIVATIVES AND USES THEREOF | MEDICON PHARMACEUTICALS, INC. | 2013-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225529-A1 | PHOSPHO-ESTER DERIVATIVES AND USES THEREOF | PHOSPHO1, PIK3CA, PYGB | TSHR 4716/4885CYP3A4 1824/4885LPAR3 369/4885 |
| US-20140315834-A1 | COMPOUNDS AND COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF INFLAMMATION-RELATED DISORDERS, PAIN AND FEVER, SKIN DISORDERS, CANCER AND PRECANCEROUS CONDITIONS THEREOF | HMGB1, PTGES, FDPS | TSHR 4313/4885CYP3A4 311/4885LPAR3 3492/4885 |
| US-20140088045-A1 | PRODUCT COMPRISING A NICOTINE-CONTAINING MATERIAL AND AN ANTI-CANCER AGENT | TNF, HUNK, NAPRT | TSHR 4361/4885CYP3A4 4129/4885LPAR3 1761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.